$HLVX
HilleVax, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022011331 Filed on June 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.603M $1.198M
YoY Change 117.28%
% of Gross Profit
Research & Development $2.500M $267.0K
YoY Change 836.33%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $11.31M $1.465M
YoY Change 672.29%
Operating Profit -$11.31M -$1.465M
YoY Change 672.29%
Interest Expense $2.064M $9.000K
YoY Change 22833.33%
% of Operating Profit
Other Income/Expense, Net -$56.57M -$81.00K
YoY Change 69743.21%
Pretax Income -$67.89M -$1.546M
YoY Change 4291.14%
Income Tax
% Of Pretax Income
Net Earnings -$67.89M -$1.546M
YoY Change 4291.14%
Net Earnings / Revenue
Basic Earnings Per Share -$10.06 -$0.32
Diluted Earnings Per Share -$10.06 -$0.32
COMMON SHARES
Basic Shares Outstanding 6.749M 4.803M
Diluted Shares Outstanding 6.749M 4.803M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $111.3M
YoY Change
Cash & Equivalents $111.3M $40.00K
Short-Term Investments
Other Short-Term Assets $480.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $111.7M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $176.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.788M
YoY Change
Total Long-Term Assets $2.964M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $111.7M
Total Long-Term Assets $2.964M
Total Assets $114.7M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.010M
YoY Change
Accrued Expenses $4.778M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $175.3M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $282.9M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $1.000K
YoY Change
Total Long-Term Liabilities $1.000K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $282.9M
Total Long-Term Liabilities $1.000K
Total Liabilities $283.1M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$173.1M
YoY Change
Common Stock $4.699M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$168.4M -$4.320M
YoY Change
Total Liabilities & Shareholders Equity $114.7M
YoY Change

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$67.89M -$1.546M
YoY Change 4291.14%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.72M -$417.0K
YoY Change 2469.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.500M $0.00
YoY Change
Cash From Investing Activities -$2.500M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -99.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -10.72M -417.0K
Cash From Investing Activities -2.500M 0.000
Cash From Financing Activities -99.00K 0.000
Net Change In Cash -13.31M -417.0K
YoY Change 3092.81%
FREE CASH FLOW
Cash From Operating Activities -$10.72M -$417.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001888012
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-41365
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
HILLEVAX, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0545060
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100 - #9995
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
213-5054
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
HLVX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33427209
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111252000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124566000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
480000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
141000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
111732000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
124707000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
176000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2788000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2221000
CY2022Q1 us-gaap Assets
Assets
114696000
CY2021Q4 us-gaap Assets
Assets
127159000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
4010000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1024000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4778000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9164000
CY2022Q1 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
4885000
CY2021Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
2821000
CY2022Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
175349000
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
158276000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
35000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
32000
CY2022Q1 hlvx Warrant Liabilities Related Party
WarrantLiabilitiesRelatedParty
93869000
CY2021Q4 hlvx Warrant Liabilities Related Party
WarrantLiabilitiesRelatedParty
56445000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
282926000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227762000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
153000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000
CY2022Q1 us-gaap Liabilities
Liabilities
283068000
CY2021Q4 us-gaap Liabilities
Liabilities
227916000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9225321
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9225321
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6897450
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6599886
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4698000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4426000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173071000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105184000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-168372000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
114696000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127159000
CY2022Q1 us-gaap Related Party Costs
RelatedPartyCosts
1422000
CY2021Q1 us-gaap Related Party Costs
RelatedPartyCosts
15000
CY2022Q1 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
6211000
CY2021Q1 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
267000
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2500000
CY2022Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
26000
CY2021Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
165000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2603000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1198000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11314000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1465000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11314000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1465000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6000
CY2022Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
529000
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
9000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2064000
CY2021Q1 us-gaap Interest Expense
InterestExpense
9000
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
4378000
CY2021Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
73000
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
17073000
CY2021Q1 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
73000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
37424000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-56573000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-81000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-67887000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1546000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.06
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.06
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6748668
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6748668
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4802907
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4802907
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
272000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-67887000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-168372000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2773000
CY2021Q1 hlvx Vesting Restrictions Placed On Previously Issued And Outstanding Common Stock
VestingRestrictionsPlacedOnPreviouslyIssuedAndOutstandingCommonStock
1000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1546000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-4320000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-67887000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-1546000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
272000
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
4378000
CY2021Q1 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
73000
CY2022Q1 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
17073000
CY2021Q1 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
73000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
37424000
CY2022Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2500000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
CY2022Q1 hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
CY2021Q1 hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
12000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
339000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10000
CY2022Q1 hlvx Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
-3402000
CY2021Q1 hlvx Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
67000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1868000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1037000
CY2022Q1 hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
529000
CY2021Q1 hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
9000
CY2022Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2064000
CY2021Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
9000
CY2022Q1 hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
4000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10715000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-417000
CY2022Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2500000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
99000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-99000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13314000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-417000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
124566000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
457000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111252000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40000
CY2022Q1 us-gaap Stock Issued1
StockIssued1
548000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:16.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
44000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
44000
CY2022Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2800000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2200000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
141000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
44000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
35000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
200000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2476653
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1663801
CY2022Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P54M
CY2022Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.060
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
33000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
176000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
35000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
9000000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2625435
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
297564
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2327871
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.025
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.881
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.895
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
272000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.92
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6000000.0
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7290497

Files In Submission

Name View Source Status
0000950170-22-011331-index-headers.html Edgar Link pending
0000950170-22-011331-index.html Edgar Link pending
0000950170-22-011331.txt Edgar Link pending
0000950170-22-011331-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hlvx-20220331.htm Edgar Link pending
hlvx-20220331.xsd Edgar Link pending
hlvx-20220331_cal.xml Edgar Link unprocessable
hlvx-20220331_def.xml Edgar Link unprocessable
hlvx-20220331_htm.xml Edgar Link completed
hlvx-20220331_lab.xml Edgar Link unprocessable
hlvx-20220331_pre.xml Edgar Link unprocessable
hlvx-ex31_1.htm Edgar Link pending
hlvx-ex31_2.htm Edgar Link pending
hlvx-ex32_1.htm Edgar Link pending
hlvx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending